World's leading genomics system to power the first
longitudinal study of tumor-normal whole genome data matched in
real time with patient progress and outcomes, freely available
worldwide
- The San Antonio 1000
Cancer Genome Project is collecting tumor and normal patient
samples in the ten most common cancers from across a single
metropolitan area
- WuXi NextCODE's CLIA laboratory will have sequenced the
majority by year end.
- The same WuXi NextCODE informatics driving big precision
medicine efforts in the US, UK, Qatar and China will then catalogue the key differences
between tumor and normal sequence
- START is anonymously linking that data with treatment and
outcomes data, creating a unique resource for directly applying
genomics research to benefit patient care
SAN ANTONIO, SHANGHAI, CAMBRIDGE,
Massachusetts, REYKJAVIK,
Iceland, and MADRID,
Nov. 3, 2015 /PRNewswire/ -- The San
Antonio 1000 Cancer Genomes Project (SA1kCGP), WuXi NextCODE, and
South Texas Accelerated Research Therapeutics (START) today
announced a partnership that will enable San Antonio's pioneering city-wide cancer
genomics effort to contribute directly to improving the clinical
treatment of cancer around the globe. The SA1kCGP brings together
hundreds of doctors, oncologists and surgeons, and a thousand
patients to create the basis for this resource: tumor samples from
breast, lung, prostate, skin, colorectal, uterine, pancreatic,
ovarian, stomach, brain cancers, collected at the time of
diagnosis.
Logo - http://photos.prnewswire.com/prnh/20151102/283127LOGO
Logo - http://photos.prnewswire.com/prnh/20151102/283128LOGO
Logo - http://photos.prnewswire.com/prnh/20150325/194344LOGO
START, which operates the world's largest Phase I medical
oncology program through clinical sites in the US, China and Spain, has contracted with WuXi NextCODE, a
precision medicine company using the genome to improve health
worldwide, to sequence and interpret the samples. WuXi NextCODE
will utilize its CLIA sequence laboratory and its HIPAA-compliant
NextCLOUD™ secondary analysis and storage solution, powered by
DNAnexus. START is connecting this "delta file" to anonymized
patient electronic clinical records using the Medidata Rave™
system, and will make it available to qualified researchers and
clinicians via the cloud.
"We're excited to announce the next phase in this pioneering
effort, turning the talents and generosity of our community into
better outcomes for patients," said Aimee
Locke, founder and president of SA1kCGP. "As global leaders
in clinical development and genomics, and with operations in the
US, Europe and China, our partners WuXi NextCODE and START
are uniquely placed to help us deliver on this vision."
"Our three organizations share the mission of using our unique
capabilities and assets to create better medicine for patients
everywhere," said Dr Anthony
Tolcher, director of clinical research at START. "WuXi
NextCODE was the logical partner in genomics. They bring to this
project the same expertise they are deploying in large-scale
precision oncology initiatives from Genomics England to
Qatar, backed by the renowned
clinical development capabilities of WuXi AppTec."
"San Antonio is innovating
locally and impacting globally, an approach to precision medicine
we are thrilled to be a part of," said Hannes Smarason, co-founder,
President and COO of WuXi NextCODE, a wholly owned subsidiary of
WuXi AppTec (NYSE:WX). "This is a pathbreaking resource in scope,
scale, and with START's hallmark clinical rigor. We are all focused
here on speeding the delivery of the latest in genome-driven
therapy straight to cancer patients, wherever they may be."
About the San Antonio
1000 Cancer Genome Project. SA1kCGP is a
pioneering cancer genome research project that has the
unprecedented support of more than 200 surgeons, oncologists, and
cancer researchers from a broad spectrum of affiliations. It is the
largest community-wide undertaking of its kind and, most
significantly, all data will be made available publicly at no cost
to researchers worldwide. The project's promise to make all data
freely available is built on the belief that no single investigator
or institution has all of the answers and encourages the
involvement of outsiders who might bring fresh ideas to the urgent
and complex problem of gene abnormalities and cancer. The
San Antonio 1000 Cancer Genome
Project is a Texas not-for-profit
501 (c) (3) established to accelerate the development of a cure for
cancer by conducting whole genome sequencing of cancerous and
normal tissues. The project will link the genetic alterations that
underlie the cancers to detailed clinical outcomes and all data
will be made available publicly at no cost to researchers
worldwide. www.sagenome.net.
About START. With centers located in
Madrid, Spain, Shanghai, China and San Antonio, Texas, START operates the
largest, global, 24-hour Phase I research organization. START's
mission is to accelerate the development of new anticancer drugs
for the purpose of improving the quality of life and survival for
patients with cancer. For information on START visit
www.startthecure.com.
WuXi NextCODE offers uniquely comprehensive and
integrated capabilities for using the genome to better diagnose
disease and create better medicine. These include a full range of
sequencing services through our CLIA-certified laboratory; the
world's leading genome sequence analysis system; a novel database
architecture that makes it possible to query, manage, store and
share massive genomic data with unrivalled speed and efficiency;
and the know-how and experience to apply genomics to optimize every
aspect of drug discovery and development. With offices in
Shanghai, Cambridge, Massachusetts and Reykjavik, we enable clinicians and
researchers at institutions and companies worldwide to use the full
power of the genome to diagnose, treat and prevent disease. WuXi
NextCODE is a wholly owned subsidiary of WuXi AppTec, the operating
subsidiaries of WuXi PharmaTech (NYSE: WX). WuXi AppTec comprises a
leading open-access R&D capability and technology platform
company serving the pharmaceutical, biotechnology, and medical
device industries, with operations in China and the United
States.
Contacts:
|
|
WuXi NextCODE
|
SA1kCGP & START
|
Edward Farmer
|
Kelly Morris
|
VP Communications & New
Ventures
|
Kelly Morris Communications
|
efarmer@wuxinextcode.com
|
kellymorrispr@gmail.com
|
781 775 6206
|
210-930-5252
|